Watertown, MA-based Tetraphase Pharmaceuticals Inc., which focuses on discovering novel antibiotics to treat drug-resistant infections, has closed the first tranche of its $25m Series B financing.
The funds will support the advancement of several novel and potent antibiotic drug candidates.
The Series B Financing and first tranche of $10m was funded by existing investors Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.
Founded in 2006, Tetraphase Pharmaceuticals was established to advance and commercialize the synthetic chemistry platform developed by Dr. Andrew Myers of Harvard University.
FinSMEs
06/10/2009